Recently, Pol θ emerged as a new promising drug target to trigger the synthetic lethality between loss of the PolQ gene and deficiencies in DSB DNA repair-related tumor suppressor genes including BRCA1/2, ATM and FANCD2 for the treatment of HDR-deficient tumors (212–214). Here, BRCA1 is linked to neoplasm.